{
    "id": 15463,
    "fullName": "FOLR1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "FOLR1 positive indicates the presence of the FOLR1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2348,
        "geneSymbol": "FOLR1",
        "terms": [
            "FOLR1",
            "FBP",
            "FOLR",
            "FRalpha"
        ]
    },
    "variant": "positive",
    "createDate": "12/18/2015",
    "updateDate": "05/15/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6703,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Mirvetuximab Soravtansine (IMGN853) treatment resulted in an overall response rate of 40% (19/48) in platinum-resistant epithelial ovarian cancer patients, with 33% (3/9) in low, 33% (5/15) in medium, and 48% (11/23) in high Folr1 expression patients (J Clin Oncol 34, 2016 (suppl; abstr 5567)).",
            "molecularProfile": {
                "id": 15726,
                "profileName": "FOLR1 positive"
            },
            "therapy": {
                "id": 3232,
                "therapyName": "Mirvetuximab Soravtansine",
                "synonyms": null
            },
            "indication": {
                "id": 2152,
                "name": "ovary epithelial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5752,
                    "pubMedId": null,
                    "title": "IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FR?)-targeting antibody-drug conjugate (ADC): Single-agent activity in platinum-resistant epithelial ovarian cancer (EOC) patients (pts).",
                    "url": "http://abstracts.asco.org/176/AbstView_176_169854.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21180,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MOv19-BBz CAR T cells demonstrated antigen-specific cytotoxicity toward FOLR1-positive ovarian cancer cell lines in culture, and resulted in tumor regression in cell line xenograft models (PMID: 21546571).",
            "molecularProfile": {
                "id": 15726,
                "profileName": "FOLR1 positive"
            },
            "therapy": {
                "id": 9584,
                "therapyName": "MOv19-BBz CAR T cells",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18450,
                    "pubMedId": 21546571,
                    "title": "In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21546571"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14953,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MORAb-202 targeted Folr1-positive tumor cells, resulted in tumor regression in patient-derived xenograft (PDX) models of triple-receptor negative breast cancer (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B115).",
            "molecularProfile": {
                "id": 15726,
                "profileName": "FOLR1 positive"
            },
            "therapy": {
                "id": 7224,
                "therapyName": "MORAb-202",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11839,
                    "pubMedId": null,
                    "title": "MORAb-202: a folate receptor alpha (FRA)-targeting antibody-drug conjugate, exhibiting targeted antitumor activity and bystander elimination of cancer-associated fibroblasts",
                    "url": "http://mct.aacrjournals.org/content/17/1_Supplement/B115"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 15726,
            "profileName": "FOLR1 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}